1. Pericardial fat, thoracic peri-aortic adipose tissue, and systemic inflammatory marker in nonalcoholic fatty liver and abdominal obesity phenotype.
- Author
-
Yun CH, Jhuang JR, and Tsou MT
- Subjects
- Adult, Aorta, Thoracic, Cross-Sectional Studies, Female, Humans, Male, Middle Aged, Non-alcoholic Fatty Liver Disease blood, Non-alcoholic Fatty Liver Disease physiopathology, Obesity, Abdominal blood, Obesity, Abdominal physiopathology, Pericardium, Phenotype, Predictive Value of Tests, Retrospective Studies, Up-Regulation, Adipose Tissue physiopathology, Adiposity, Anthropometry, C-Reactive Protein analysis, Immunoassay, Inflammation Mediators blood, Non-alcoholic Fatty Liver Disease diagnosis, Obesity, Abdominal diagnosis
- Abstract
Researchers have conducted many studies about the relationships between peri-cardiovascular fat, nonalcoholic fatty liver disease (NAFLD), waist circumference, and cardiovascular disease (CVD). Nevertheless, the relationship between NAFLD and pericardial fat (PCF)/thoracic peri-aortic adipose tissue (TAT) phenotypes was still unknown. This study aimed to explore whether PCF/TAT was associated with NAFLD/abdominal obesity (AO) phenotypes in different high-sensitivity C-reactive protein (hs-CRP) levels. We consecutively studied 1655 individuals (mean age, 49.44 ± 9.76 years) who underwent a health-screening program. We showed a significant association between PCF/TAT and NAFLD/AO phenotypes in the cross-sectional study. We observed that the highest risk occurred in both abnormalities' groups, and the second highest risk occurred in the AO-only group. Subjects with AO had a significantly increased risk of PCF or TAT compared to those with NAFLD. Notably, the magnitude of the associations between PCF/TAT and NAFLD/AO varied by the level of systemic inflammatory marker (hs-CRP level). We suggested that people with AO and NAFLD must be more careful about changes in PCF and TAT. Regular measurement of waist circumference (or AO) can be a more accessible way to monitor peri-cardiovascular fat (PCF and TAT), which may serve as a novel and rapid way to screen CVD in the future., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF